Skip to main content
Caplight Logo









Bobcat Bio

Bobcat Bio

Private
Hummelstown, PennsylvaniaHealthcare & Life Scienceshttps://sirpantimmunotx.com

Last Round

Series A

Extension

Feb 25, 2025

Est. Valuation

$49.8M

Total Funding Raised

$87.49M

Company Overview

Bobcat Bio is a biotechnology company that develops autologous macrophage cell therapies for the treatment of solid tumors and hematological malignancies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyimmunotherapymacrophage therapyautologous cell therapycancer immunotherapysolid tumor treatmentSIRPα-CD47 pathwayclinical-stage biotechinvestigational new drugINDcancer researchbiopharmanext-gen immunotherapycheckpoint inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bobcat Bio Comparables

Compare Bobcat Bio with similar companies based on industry and business-model similarity.

Bobcat Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avstera Therapeutics
83%
Inceptor Bio
82%
Carisma Therapeutics
81%

Bobcat Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 25, 2025
GrantAug 8, 2024
Series BJan 22, 2024
GrantSep 1, 2023
Series ASep 29, 2021
Series A
Jul 23, 2021

Bobcat Bio Investors

Notable investors and investment history

Bobcat Bio investors
InvestorRounds
National Cancer InstituteGrant
BioAdvance CapitalSeries A, Series A Extension
BiolocitySeries B
Bios PartnersSeries A Extension, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 29, 2021

    $27M round led by Bios Partners.

Bobcat Bio Filings

Explore SEC and related filing metadata, where available.

Bobcat Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Bobcat Bio's valuation, stock price, and market status.

Is Bobcat Bio a public or private company?

Bobcat Bio is a private company.

What is the current stock price of Bobcat Bio?

Bobcat Bio is a private company, so its shares have no public market price. Caplight tracks Bobcat Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Bobcat Bio worth (valuation)?

Bobcat Bio's valuation is estimated at $49.8M based on funding round data.

Can I buy Bobcat Bio stock?

Bobcat Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Bobcat Bio's last funding round?

Bobcat Bio's most recent funding round was Series A Extension on February 25, 2025.

Who are the main investors in Bobcat Bio?

Key investors in Bobcat Bio include Bios Partners.

Will Bobcat Bio IPO soon?

No public IPO plans have been announced for Bobcat Bio.

How can I track Bobcat Bio secondary market activity?

Caplight tracks bids, offers, and trades in Bobcat Bio's shares on secondary markets.

Firmographic Details

HeadquartersHummelstown, Pennsylvania
Year Founded2020
Last FundingFeb 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?